Biomolecular prognostic factors in Klatskin tumor

Zharikov Yu.O.; Kovalenko Yu.A.; Zhao A.V.

doi:https://doi.org/10.17116/hirurgia2016582-85

Zharikov Yu.O.

Institute of Surgery named after A.V. Vishnevskiy, Moscow

ORCID: 0000-0001-9636-3807

Kovalenko Yu.A.

Federal state budgetary institution «A.A. Vishnevsky Institute of Surgery», Russian Ministry of Health (director: B.A. Kubyshkin, member of Russian Academy of Sciences]

SPIN RSCI: 2809-4942
Scopus AuthorID: 57192228587
ORCID: 0000-0001-9879-6403

Zhao A.V.

FGBU "Institut khirurgii im. A.V. Vishnevskogo" Minzdrava Rossii, Moskva

ORCID: 0000-0002-2146-5136

Biomolecular prognostic factors in Klatskin tumor

Authors:

Zharikov Yu.O., Kovalenko Yu.A., Zhao A.V.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2016;(5): 82‑85

DOI: 10.17116/hirurgia2016582-85

Read: 5771 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zharikov YuO, Kovalenko YuA, Zhao AV. Biomolecular prognostic factors in Klatskin tumor. Pirogov Russian Journal of Surgery. 2016;(5):82‑85. (In Russ.)
https://doi.org/10.17116/hirurgia2016582-85

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

References:

Vishnevskij V.А., Efanov M.G., Ikramov R.Z., Nazarenko N.А., SHevchenko T.V., Ionkin D.А., CHzhao А.V. Otdalennye rezul'taty radikal'nykh i uslovno radikal'nykh rezektsij pri vorotnoj kholangiokartsinome [Long-term results of radical and conditionally radical resection for portal cholangiocarcinoma]. Аnnaly khirurgicheskoj gepatologii. 2013;18:2:9-20.(In Russian)
Dolgushin B.I., Virshke EH.R., Kosyrev V.YU., Trofimov I.А., Kukushkin А.V., CHerkasov V.А., Sergeeva O.N. Vnutriarterial'naya khimioehmbolizatsiya v lechenii neoperabel'nykh bol'nykh uzlovoj formoj kholangiokartsinomy [Intra-arterial chemoembolization in the treatment of patients with unresectable nodal cholangiocarcinoma]. Аnnaly khirurgicheskoj gepatologii. 2015;20:3:24-30.(In Russian)
Makarov E.S., Nechushkin M.I., Dolgushin B.I., Kukushkin А.V., Molodikova N.R., Kozlov O.V. Vnutriprotokovaya luchevaya terapiya neoperabel'nykh bol'nykh kholangiotsellyulyarnym rakom: tekhnicheskie aspekty i otdalennye rezul'taty [Intraductal radiotherapy of inoperable patients with cholangiocellular cancer: technical aspects and long-term results]. Аnnaly khirurgicheskoj gepatologii. 2014;19:4:48-55.(In Russian)
SHHerba А.E., Slobodin YU.V., Rummo O.O., Аvdej E.L., Fedoruk А.M., KHar'kov D.P., Korotkov S.V. KHirurgicheskoe lechenie opukholi Klatskina [Surgical treatment of Klatskin tumor]. Novosti khirurgii. 2009;17:4:92-98. (In Russian)
Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford). 2013;15(7):492-503. doi: 10.1111/j.1477-2574.2012.00616.x
Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885-1893. doi: 10.1038/bjc.2011.452
Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surgery, Gynecology & Obstetrics. 1975;140(2):170-178.
Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer. 2009;45(1):33-47. doi: 10.1016/j.ejca.2008.08.024
Cardinale V, Bragazzi MC, Carpino G, Torrice A et al. Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surgery and Nutrition. 2013;2(5):272-280. doi: 10.3978/j.issn.2304-3881.2013.10.02
Coelen RJ, Wiggers JK, Nio CY, Besselink MG, Busch OR, Gouma DJ, van Gulik TM. Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford). 2015;17(6):520-528. doi: 10.1111/hpb.12394
De Jong MC, Hong SM, Augustine MM, Goggins MG, Wolfgang CL, Hirose K, Schulick RD, Choti MA, Anders RA, Pawlik TM. Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch Surg. 2011;146(6):697-703. doi: 10.1001/archsurg.2011.122
Fingas CD, Katsounas A, Kahraman A, Siffert W, Jochum C, Gerken G, Nuckel H, Canbay A. Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1- 386C>G) in extrahepatic cholangiocarcinoma. Cancer Invest. 2010;28(5):472-478. doi: 10.3109/07357900903095714
Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31(6):1256-1263.
Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, Matsumoto J, Kawasaki R. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci. 2010;17(4):455-62. doi: 10.1007/s00534-009-0208-1
Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor- Robinson SD, Toledano MB. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56(4):848-854. doi: 10.1016/j.jhep.2011.11.015
Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973-981.
Nakanuma Y, Sasaki M, Sato Y, Ren X, Ikeda H, Harada K. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J Hepatol. 2009;1(1):35-42. doi: 10.4254/wjh.v1.i1.35
Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230(6):808-818; discussion 819.
Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Annals of Surgical Oncology. 2012;19(5):1602-1608. doi: 10.1245/s10434-011-2077-5
Nitta T, Mitsuhashi T, Hatanaka Y, Miyamoto M, Oba K, Tsuchikawa T, Suzuki Y, Hatanaka KC, Hirano S, Matsuno Y. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray. Br J Cancer. 2014;111(7):1363-1372. doi: 10.1038/bjc.2014.415
Nuzzo G, Giuliante F, Ardito F, Giovannini I et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Archives of surgery. 2012;147(1):26-34.
Otsuji H, Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Nagino M. Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection. World J Surg. 2015;39(6):1494- 1500. doi: 10.1007/s00268-015-2988-6
Paolicchi E, Pacetti P, Giovannetti E, Mambrini A, Orlandi M, Crea F, Romani AA, Tartarini R, Danesi R, Peters GJ, Cantore M. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncol Lett. 2013;6(5):1487-1491.
Regimbeau JM, Fuks D, Pessaux P, Bachellier P, Chatelain D, Diouf M, Raventos A, Mantion G, Gigot JF, Chiche L, Pascal G, Azoulay D, Laurent A, Letoublon C, Boleslawski E, Rivoire M, Mabrut JY, Adham M, Le Treut YP, Delpero JR, Navarro F, Ayav A, Boudjema K, Nuzzo G, Scotte M, Farges O. HC-AFC-2009 group. Tumour size over 3 cm predicts poor short-term outcomes after major liver resection for hilar cholangiocarcinoma. By the HC-AFC-2009 group. HPB (Oxford). 2015;17(1):79-86. doi: 10.1111/hpb.12296
Sato Y, Harada K, Itatsu K, Ikeda H, Kakuda Y, Shimomura S, Shan Ren X, Yoneda N, Sasaki M, Nakanuma Y. Epithelial- esenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol. 2010;177(1):141-152. doi: 10.2353/ajpath.2010.090747
Suarez-Munoz MA, Fernandez-Aguilar JL, Sanchez-Perez B, Perez- Daga JA, Garcia-Albiach B, Pulido-Roa Y, Marin-Camero N, Santoyo- Santoyo J. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013;5(7):132-138. doi: 10.4251/wjgo.v5.i7.132
Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T, Hayashi H, Motoi F, Egawa S. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17(4):463- 469. doi: 10.1007/s00534-009-0206-3
Wiggers JK, Ruys AT, Groot Koerkamp B, Beuers U, ten Kate FJ, van Gulik TM. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(8):1582- 1594. doi: 10.1111/jgh.12620
Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818- 829. doi: 10.1016/j.devcel.2008.05.009
Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Disease models & mechanisms. 2013;6(2):281-292. doi: 10.1242/dmm.010561
Zhao W, Zhang B, Guo X, Zhang X, Hu J, Hu X, Lu Y. Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma. Cancer Biomark. 2014;14(4):197-202. doi: 10.3233/CBM-140393